News | July 16, 2024
Merck completes acquisition of EyeBio
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated
